These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 21600232)
21. Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III. Finlay-Schultz J; Gillen AE; Brechbuhl HM; Ivie JJ; Matthews SB; Jacobsen BM; Bentley DL; Kabos P; Sartorius CA Cancer Res; 2017 Sep; 77(18):4934-4946. PubMed ID: 28729413 [TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Raso MG; Behrens C; Herynk MH; Liu S; Prudkin L; Ozburn NC; Woods DM; Tang X; Mehran RJ; Moran C; Lee JJ; Wistuba II Clin Cancer Res; 2009 Sep; 15(17):5359-68. PubMed ID: 19706809 [TBL] [Abstract][Full Text] [Related]
23. [Expression of CD133 and Notch1 in non-small cell lung cancer and the clinicopathological significance]. Zhou L; Wu S; Yu L; Gong X; Song W; Cheng Z Nan Fang Yi Ke Da Xue Xue Bao; 2015 Feb; 35(2):196-201. PubMed ID: 25736112 [TBL] [Abstract][Full Text] [Related]
24. Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B. Wu J; Richer J; Horwitz KB; Hyder SM Cancer Res; 2004 Mar; 64(6):2238-44. PubMed ID: 15026368 [TBL] [Abstract][Full Text] [Related]
25. Complex agonist-like properties of ICI 182,780 (Faslodex) in human breast cancer cells that predominantly express progesterone receptor-B: implications for treatment resistance. Wu J; Liang Y; Nawaz Z; Hyder SM Int J Oncol; 2005 Dec; 27(6):1647-59. PubMed ID: 16273221 [TBL] [Abstract][Full Text] [Related]
26. Mechanism of action of bolandiol (19-nortestosterone-3beta,17beta-diol), a unique anabolic steroid with androgenic, estrogenic, and progestational activities. Attardi BJ; Page ST; Hild SA; Coss CC; Matsumoto AM J Steroid Biochem Mol Biol; 2010 Feb; 118(3):151-61. PubMed ID: 19941958 [TBL] [Abstract][Full Text] [Related]
28. Progesterone receptor (PR) polyproline domain (PPD) mediates inhibition of epidermal growth factor receptor (EGFR) signaling in non-small cell lung cancer cells. Kawprasertsri S; Pietras RJ; Marquez-Garban DC; Boonyaratanakornkit V Cancer Lett; 2016 May; 374(2):279-91. PubMed ID: 26892043 [TBL] [Abstract][Full Text] [Related]
29. Specificities of lung adenocarcinoma in women who have never smoked. Mazières J; Rouquette I; Lepage B; Milia J; Brouchet L; Guibert N; Beau-Faller M; Validire P; Hofman P; Fouret P J Thorac Oncol; 2013 Jul; 8(7):923-9. PubMed ID: 23608817 [TBL] [Abstract][Full Text] [Related]
30. G protein-coupled estrogen receptor (GPER) mediates NSCLC progression induced by 17β-estradiol (E2) and selective agonist G1. Liu C; Liao Y; Fan S; Tang H; Jiang Z; Zhou B; Xiong J; Zhou S; Zou M; Wang J Med Oncol; 2015 Apr; 32(4):104. PubMed ID: 25744245 [TBL] [Abstract][Full Text] [Related]
31. Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy. Kubo T; Takigawa N; Osawa M; Harada D; Ninomiya T; Ochi N; Ichihara E; Yamane H; Tanimoto M; Kiura K Cancer Sci; 2013 Jan; 104(1):78-84. PubMed ID: 23066953 [TBL] [Abstract][Full Text] [Related]
32. Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest. Lundholm L; Hååg P; Zong D; Juntti T; Mörk B; Lewensohn R; Viktorsson K Cell Death Dis; 2013 Jan; 4(1):e478. PubMed ID: 23370278 [TBL] [Abstract][Full Text] [Related]
33. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. Leung EL; Fiscus RR; Tung JW; Tin VP; Cheng LC; Sihoe AD; Fink LM; Ma Y; Wong MP PLoS One; 2010 Nov; 5(11):e14062. PubMed ID: 21124918 [TBL] [Abstract][Full Text] [Related]
34. Activation of D2 Dopamine Receptors in CD133+ve Cancer Stem Cells in Non-small Cell Lung Carcinoma Inhibits Proliferation, Clonogenic Ability, and Invasiveness of These Cells. Roy S; Lu K; Nayak MK; Bhuniya A; Ghosh T; Kundu S; Ghosh S; Baral R; Dasgupta PS; Basu S J Biol Chem; 2017 Jan; 292(2):435-445. PubMed ID: 27920206 [TBL] [Abstract][Full Text] [Related]
35. Estradiol and nicotine exposure enhances A549 bronchioloalveolar carcinoma xenograft growth in mice through the stimulation of angiogenesis. Jarzynka MJ; Guo P; Bar-Joseph I; Hu B; Cheng SY Int J Oncol; 2006 Feb; 28(2):337-44. PubMed ID: 16391787 [TBL] [Abstract][Full Text] [Related]
36. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer. Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091 [TBL] [Abstract][Full Text] [Related]
37. High CD133 expression in the nucleus and cytoplasm predicts poor prognosis in non-small cell lung cancer. Huang M; Zhu H; Feng J; Ni S; Huang J Dis Markers; 2015; 2015():986095. PubMed ID: 25691807 [TBL] [Abstract][Full Text] [Related]
38. Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Di Nunno L; Larsson LG; Rinehart JJ; Beissner RS Arch Pathol Lab Med; 2000 Oct; 124(10):1467-70. PubMed ID: 11035577 [TBL] [Abstract][Full Text] [Related]
39. Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer. Abe K; Miki Y; Ono K; Mori M; Kakinuma H; Kou Y; Kudo N; Koguchi M; Niikawa H; Suzuki S; Evans DB; Sugawara S; Suzuki T; Sasano H Hum Pathol; 2010 Feb; 41(2):190-8. PubMed ID: 19800101 [TBL] [Abstract][Full Text] [Related]
40. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]